Previously, we and others have demonstrated the association of a C/T single nucleotide polymorphism (SNP), in the Kozak sequence of CD40, with Graves' disease (GD). Here, using an expanded data set of patients, we confirm the association of the CD40 SNP with GD (n ¼ 210, P ¼ 0.002, odds ratio (OR) ¼ 1.8). Subset analysis of patients with persistently elevated thyroid peroxidase (TPO) and/or thyroglobulin (Tg) antibodies (Abs), (TPO/Tg Abs), after treatment (n ¼ 126), revealed a significantly stronger association of the SNP with disease (P ¼ 5.2 Â 10 À5 , OR ¼ 2.5) than in GD patients who were thyroid antibodynegative. However, the CD40 SNP was not associated with TPO/Tg Abs in healthy individuals. Next, we tested the CD40 SNP for association with Myasthenia Gravis (MG), which, like GD is an antibody-mediated autoimmune condition. Analysis of 81 MG patients found no association of the SNP with disease. Functional studies revealed significant expression of CD40 mRNA and protein in the thyroid (target tissue in GD) but not in skeletal muscle (target tissue in MG). Combined, our genetic and tissue expression data suggest that the CD40 Kozak SNP is specific for thyroid antibody production involved in the etiology of GD. Increased thyroidal expression of CD40 driven by the SNP may contribute to this disease specificity.
Introduction
Of the myriad of human autoimmune afflictions, Graves' disease (GD) represents one of the most common, with a population prevalence in the US approaching 1%. 1 Characterized by thyrotoxicosis, diffuse goiter and the presence of stimulating TSH receptor antibodies, 2 GD develops as a result of a sequence of genetic and environmental events. 3, 4 An inherent genetic predisposition, 5 combined with a putative external trigger, such as infection 6 or trauma, results in the activation of thyroidautoreactive CD4 þ T cells which infiltrate the thyroid gland. The thyroid infiltrating T cells activate B cells to secrete TSH receptor stimulating antibodies that induce proliferation of thyrocytes and secretion of excess thyroid hormones, resulting in the classic symptoms of GD. 7 Although the exact nature of the external trigger in GD etiology remains unknown, 8 the genetic components of the condition's etiology are being unraveled. 9, 10 The CD40 gene has emerged as an important participant in the etiology of GD. Whole genome screens, which we have performed, 11, 12 and linkage studies carried out by others, 13 showed that the CD40 gene locus was linked with GD. Sequencing of the entire CD40 gene allowed the identification of a C/T polymorphism in the Kozak sequence of the 5 0 UTR. Subsequent case-control association studies demonstrated an association of the CC genotype with GD. 12 With the exception of a sole report, 14 the association between the CC genotype and GD has now been replicated in several studies, performed in different populations, including Caucasians, 12, 15 Koreans 16 and Japanese 17, 18 (an additional report purporting a lack of association between the C allele and GD 19 was found, upon re-analysis, to show an association between the CC genotype and GD 20 ). Moreover, a meta-analysis of all studies showed a highly significant association between the CC genotype and GD. 15 Recent studies by our laboratory have shed light on possible mechanisms by which the C allele of the CD40 Kozak single nucleotide polymorphism (SNP) can contribute to the etiology of GD. Using in vitro studies, we have demonstrated that the C allele of the CD40 Kozak SNP increases the translational efficiency of nascent CD40 mRNA transcripts, resulting in 15-32% more CD40 protein than that seen in the context of the T allele. 21 Hence, we proposed that there exists a translational pathophysiological aspect to GD, owing to subtle changes in the levels of CD40 protein, with increased CD40 expression contributing to disease etiology.
The CD40 gene product represents a molecular linchpin in the activation of B cells. A member of the tumor necrosis factor receptor (TNFR) family of molecules, 22 CD40 is expressed on all non-terminally differentiated B cells. Moreover, the fundamental role that CD40 plays in B-cell activation is demonstrated by the fact that its ligation provides the requisite co-stimulatory signal for B-cell proliferation, immunoglobulin class switching, antibody secretion, the prevention of apoptosis of germinal-center B cells, affinity maturation and the generation of memory cells (reviewed by Clark et al. 23 ). The immune system defects seen both in patients with naturally occurring CD40 mutations (HIGM3 (hyper IgM syndrome)), and in CD40 knockout mice (reviewed by Lougaris et al. 24 ), have shown the absolute requirement of CD40 for the development of a humoral immune response.
Not unexpectedly, in light of what is understood about its functionality, the CD40 molecule and its pathway have been shown to be associated in a number of autoimmune diseases with a strong humoral component, including experimental models of autoimmune myasthenia gravis (MG) 25 and GD. 26, 27 Owing to the importance of the CD40 gene in humoral-mediated autoimmunity and the functional consequences of the polymorphism, we asked whether the CD40 Kozak SNP was associated with antibody production in autoimmune conditions other than GD. Intriguingly, we found no association of the CD40 Kozak SNP with MG, a disease mediated by autoantibodies against the nicotinic acetylcholine receptor (AChR) (reviewed by Drachman 28 and Conti-Fine et al. 29 ), or with the production of thyroid antibodies in the absence of GD, suggesting that the association is specific for the autoantibodies that mediate GD.
Results
Characteristics of the data set GD patients. We analyzed 210 GD patients (171 females (81%) and 39 males (19%)). The average age of onset of GD was 41.7 years (range 13-78). Of the 170 GD patients whose thyroid antibody (thyroid peroxidase and thyroglobulin antibody (TPO/Tg Ab)) levels were available, 126 (74%) had positive thyroid antibodies after treatment and restoration of euthyroidism. Fifty percent of the GD patients had ophthalmopathy, and 69% were treated with radio-iodine ablation (Table 1a) .
MG patients. We studied 86 MG patients (49 females (57%) and 37 males (43%)). The average age of onset of disease was 43 (range 20-79). Of the 86 MG patients, 46 (53%) had positive TPO and/or Tg antibodies, indicating an association between MG and thyroid autoimmunity. Moreover, 22 MG patients (26%) had clinical autoimmune thyroid disease (GD or HT) (Table 1b) .
Analysis of the CD40 Kozak SNP in GD patients and controls All GD patients. We have previously shown a significant association between the CC genotype of the CD40 Kozak SNP and GD in a data set of 154 GD patients and 118 Caucasian controls.
12 Therefore, first we tested the CD40 Kozak SNP in an expanded data set consisting of 210 GD patients and 271 Caucasian controls. As we found before, there was a significant association of GD with the CD40 Kozak SNP. The CC genotype was present in 134/210 (63.8%) of GD patients and in 135/271 (49.8%) of controls (P ¼ 0.002, odds ratio (OR) ¼ 1.78) (Table 2a) .
GD patients with positive TPO/Tg Abs after therapy. Previous studies have shown that anti-thyroid therapy for GD is associated with decreased levels of thyroid antibodies. 30 Of the 210 GD patients, TPO/Tg Ab (anti-TPO and anti-Tg antibody) levels were available in 170. When we subset these 170 patients into those who had persistently increased TPO/Tg Abs following restoration of euthyroidism with therapy (anti-thyroid medications, radio-iodine ablation or thyroidectomy), and those with negative TPO/Tg Abs after therapy, the association with the CD40 Kozak SNP became even stronger. Among the TPO/Tg Ab-positive GD patients, 90/126 (71.4%) had the CC genotype, and among the TPO/Tg Ab-negative GD patients, 23/44 (52.3%) had the CC genotype (Pvalue ¼ 5.2 Â 10 À5 for the GD þ TPO/Tg Ab vs controls; P-value ¼ 0.02 for the GD þ TPO/Tg Ab vs GD no TPO/ Tg Ab, Table 2a ). This may suggest that the association of the CC genotype with GD is specific for the subset of GD patients with persistently elevated TPO/Tg Abs.
Healthy individuals with TPO/Tg Abs only. To test whether the association of the CD40 Kozak SNP was a general association with the production of thyroid antibodies, we analyzed the frequencies of the CC genotype in a group of healthy individuals with positive TPO/Tg Abs (anti-TPO and/or anti-Tg antibodies) (n ¼ 48) and compared them with controls without 
CD40 expression in different tissues
Quantitative RT-PCR analysis. To test whether the thyroid specificity of the CD40 association was because of tissue-specific expression of CD40, we determined the CD40 mRNA levels in several distinct tissues (trachea, blood, skeletal muscle, spleen, thymus, brain, ovary, thyroid, and lymph node), using quantitative reverse transcription-polymerase chain reaction (RT-PCR). Analysis revealed that CD40 was expressed in all tissues tested; however, expression levels differed considerably across the tissues, with brain and skeletal muscle expressing relatively low levels of CD40, and lymph node, trachea, and thyroid showing robust expression ( Figure 1a and b). CD40 mRNA levels were not significantly different between the thyroid and lymph node tissues (P ¼ 0.08). In contrast, CD40 mRNA levels in the thyroid (target tissue in GD) were significantly higher than in skeletal muscle (target tissue in MG; P ¼ 0.0075) . All values were normalized against a b actin control. There was nearly a 10-fold difference between CD40 mRNA levels in the thyroid (target organ in GD) and in the skeletal muscle (target organ in MG), suggesting that target organ CD40 expression may play a role in the development of GD.
( Figure 1 ). As it was possible that the differences in CD40 mRNA levels in the various tissues were due to resident blood cells, we determined tissue CD19 and CD20 mRNA levels (as most CD40 expression in peripheral blood cells comes from B cells, and CD19 and CD20 are B cell-specific markers 31, 32 ) , to assess putative levels of tissue contamination by blood. As shown in Figure 2 , high CD19 and CD20 mRNA levels were seen only in lymph node, spleen, and blood; levels were minimal in all other tissues tested. Thus, the differences in CD40 mRNA expression in the tissues most likely reflect intrinsic tissue expression of CD40. The high levels of CD40 gene expression in the thyroid may suggest that the CD40 gene is associated only with autoimmune diseases, where it is highly expressed in the target tissues (e.g., thyroid in GD).
Western blot analysis. To test differences in CD40 tissue expression, at the protein level, we performed Western blot analyses of CD40 expression in thyroid and skeletal muscle tissues. To rule out blood contamination of the tissues, we stripped the CD40 blot and re-probed for CD22 (a B-cell marker, expressed on the surface of mature IgD þ B cells reviewed by Tedder et al.
33
) expression levels in the tissues. Sample lanes were as follows:
(1) BJAB cell extract, (2) human peripheral B cells, combined from three different individuals, (3) human thyroidal tissue, (4) human thyroidal tissue from a second individual and (5) human skeletal muscle. As shown in Figure 3b , no CD22 protein was detected in both muscle and thyroid tissues, ruling out significant blood contamination. In contrast, high levels of expression of CD40 were seen in thyroid tissue but not in skeletal muscle tissue, corroborating the results of the quantitative RT-PCR results (Figure 3a) . Interestingly, the BJAB cell line and peripheral B cells showed a CD40 product in the expected 45-50 kDa range, 34, 35 whereas the CD40 protein from the thyroid migrated at a slightly higher molecular weight, suggestive of different degrees of post-translational modification (e.g., glycosylation) in different tissues (Figure 3a) . Combined, these data suggest that differences in CD40 tissue expression may explain the tissue specificity of the association of the CD40 Kozak SNP with autoimmunity.
Discussion
Previously, we 12 and others [15] [16] [17] [18] have shown that a SNP, in the Kozak sequence of the CD40 gene, is associated , showing significant CD20 expression only in lymph node, spleen and thymus. All other tissues did not show significant CD20 expression ruling out blood contamination. (d) CD20 mRNA levels in blood and in thyroid and muscle tissues obtained at surgery, again demonstrating significant expression of CD20 only in blood but not in thyroid or muscle. Altogether, these data demonstrated that there was no significant blood contamination of the tested tissues. Thus, the differences in CD40 mRNA expression levels between these tissues most likely represent differences in intrinsic tissue expression of CD40.
with GD. Recently, our group demonstrated that the C allele of this polymorphism caused a 15-32% increase in CD40 protein expression 21 relative to the T allele. Our functional and genetic data, coupled with the strong link that the CD40 molecule and its pathway possess to the potentiation of B-cell responses, allowed us to hypothesize that increased expression levels of CD40 could predispose individuals to antibody-mediated autoimmunity, in general. The current study was designed to test this hypothesis. Therefore, we extended our analysis of the CD40 Kozak SNP to search for associations with the development of thyroid antibodies without clinical disease, and with MG, which, like GD, is considered to be a classical antibody-mediated autoimmune disease. 28, 29 Initially, we expanded our data set of GD patients and healthy controls (n ¼ 210 and 271, respectively), and then used this expanded data set to analyze a subset of patients with persistently elevated TPO/Tg Abs after restoration of euthyroidism by therapy. We demonstrated, again, that the CC genotype of the CD40 Kozak SNP conferred a modest risk of disease (OR ¼ 1.78), which was statistically significant (P-value ¼ 0.002). Interestingly, subsetting of the data set revealed that the association of the SNP with GD was significantly stronger in GD patients with persistently elevated levels of thyroid antibodies (Tg and/or TPO) after treatment (P-value ¼ 5.2 Â 10 À5 OR ¼ 2.52, when comparing GD þ TPO/Tg Ab patients to healthy controls). Hence, our results suggest that the association of CD40 is specific for GD patients with persistently elevated levels of thyroid antibodies. Why would the association be significantly stronger in this subset of patients? One potential explanation could be that, as there are a number of genes involved in the etiology of GD, CD40 may play a role only in the subset of GD patients in whom the disease is characterized by persistent TPO/Tg Abs after therapy and restoration of euthyroidism. Perhaps, in different subsets of GD patients, other genes play a major role (e.g., CTLA-4 36 or the TSH receptor 37 ). Therefore, the same autoimmune condition may have different molecular etiologies, while having identical clinical manifestations. Indeed, our previous analysis has shown evidence for genetic heterogeneity at the CD40 gene locus. 11, 12 It should be noted that we have grouped together individuals treated by anti-thyroid medications, and individuals who underwent thyroid ablation (subset analysis was not possible owing to the small number of patients in each subset). Therefore, the association of the CD40 CC SNP genotype with persistently elevated TPO/ Tg Abs in GD patients may reflect higher expression levels of CD40 in B cells of these individuals, perpetuating TPO/Tg Ab production in patients even after thyroid ablative therapy.
We next analyzed the contribution of the CD40 Kozak polymorphism to the evolution of thyroid autoantibodies (TPO/Tg Abs). TPO/Tg Abs, which can be found in greater than 10% of healthy euthyroid individuals in the US, 38 are associated with increased risk for future development of clinical autoimmune thyroid disease. 39 Hence, understanding the molecular basis for their production is important, both in terms of disease prediction, and possibly in terms of disease prevention strategies. Comparing a group of healthy, thyroid antibody-positive individuals to our 271 thyroid antibodynegative controls did not show a significant association with the CD40 polymorphism. Thus, the CD40 SNP is uniquely associated with GD and does not seem to contribute to the development of TPO/Tg Abs, in general.
Finally, we sought to determine whether the polymorphism plays a role in MG. MG and GD share a commonality, in terms of their respective pathophysiologies. MG, like GD, is mediated by the presence of autoantibodies directed against a receptor protein.
However, in the case of MG, these autoantibodies are directed against the nicotinic AchR, disrupting the integrity of neuromuscular communications (reviewed by Drachman 28 and by Conti-Fine et al. 29 ). Both GD and MG share common associations with MHC II and CTLA-4 9, [40] [41] genes. Although CD40 has not been reported to have an association with MG, work with the experimental MG model in mice has clearly shown that the CD40 pathway is critical for disease development. 25 Hence, CD40 makes for a good common candidate gene for these two autoimmune diseases.
Comparing 81 MG patients with the 271 healthy controls revealed no association of the CD40 polymorphism with disease. Furthermore, no association was detected even when the analysis was restricted to 42 MG patients who tested positive for thyroid antibodies (Tg and/or TPO), albeit the numbers in this analysis were relatively small (Table 2b) , and a weak association (ORo2.81, Table 3 ) cannot be ruled out. Thus, our data suggest that the CD40 Kozak polymorphism, rather than predisposing to multiple autoimmune conditions, might be specific to the pathophysiology of GD. What could be the mechanistic basis for the specificity of a SNP, in an immune regulatory gene (CD40), to one specific auto- immune disease (GD)? When one compares GD to MG, disease specificity may arise due to the differential expression of CD40 in the target tissues of the autoimmune response. Thus, when significant expression of CD40 in the target tissue exists at baseline (e.g., in the thyroid), it may play a role in the etiology of the disease, whereas when its expression is low in the target tissue (e.g., skeletal muscle) the etiology of disease is not influenced by it. Indeed, our analysis using both quantitative RT-PCR and Western blotting has shown that CD40 expression is significantly higher in the thyroid compared to skeletal muscle (Figures 1 and 3) . Our findings are in accordance with the literature, as it has been reported that CD40 was undetectable, via immunohistochemical staining, on the sarcolemma of muscle cells in healthy individuals. 42 Within the skeletal muscle, the CD40 molecule, in fact, could only be detected on some of the endomysial mononuclear cells. Thus, we hypothesize that the overexpression of CD40 on thyrocytes (driven by the CC genotype of the Kozak SNP) could augment ongoing thyroid-directed autoimmunity or perhaps act as an initiator of disease. To date, it has been shown that CD40 is expressed and is functional on human thyroid follicular cells (thyrocytes). 43 Moreover, CD40 expression in the thyroid is elevated in the context of GD, 44 where the molecule has been shown to colocalize with human leukocyte antigen (HLA)-DR. 45 Such expression data offer compelling evidence for an active role for thyroidal CD40 in the etiology or propagation of GD.
How could CD40 overexpression on thyrocytes augment thyroid-directed autoimmunity? At least two mechanisms are possible, extrinsic and intrinsic. The extrinsic mechanism is based on the fact that thyrocytes, under certain conditions (e.g., viral infection), can act as antigen-presenting cells (APCs), presenting self-peptides within HLA class II molecules to intra-thyroidal T cells. [46] [47] [48] Once the T-cell receptor has recognized the presented peptide, other surface molecules on the thyrocyte, including CD40, transmit co-stimulatory signals, which are necessary for the activation of T cells. Thus, according to the extrinsic hypothesis, overexpression of CD40 on thyrocytes, driven by the C allele of the Kozak SNP could augment the activation of T cells (Figure 4a ). The second hypothetical mechanism is an intrinsic mechanism, whereby activation of the CD40 signaling pathway within the thyrocytes could alter their physiology, leading to inflammation and autoimmunity (Figure 4b) . Indeed, our quantitative RT-PCR and Western blot analyses demonstrated high level of expression of CD40 in normal human thyroids ( Figures  1 and 3) . Even though the signaling pathways of activation of CD40 in thyrocytes have not yet been examined, these can be postulated based on data from studies of activation of necrosis factor kappa B (NFkB) by transforming growth factor-beta (TGF-b) in Graves' thyrocytes, 49 as well as of CD40 signaling in other cell types. [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] According to our intrinsic hypothesis, CD40 ligand more readily activates CD40, overexpressed on the surface of thyrocytes in individuals harboring the CC genotype. Once activated, CD40 receptors multimerize, recruiting TNF-receptor associated factors (TRAFs) to their cytoplasmic tails. Downstream of the initial receptor ligation, TRAFs recruit and activate kinases such as inhibitor of k-B (IkB) kinase (IKK), leading to activation of NFkB pathway. NFkB is able to turn on transcription of a number of genes including cytokines, chemokines and adhesion molecules, which could augment thyroidal inflammation [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] (Figure 4b ). Moreover, activation of the CD40 pathway has been shown to activate anti-apoptotic pathways in several non-lympho- The intrinsic thyroidal CD40 model. Here, we hypothesize that stimulation of CD40 on the surface of thyrocytes leads to multimerization of CD40 receptor, followed by a downstream activation of transcription factor NFkB. NFkB is then able to upregulate a number of genes which could, potentially, contribute to a change in thyrocyte cellular physiology and induce inflammation.
cyte cell types. 60 Therefore, it is possible that CD40 overexpression on thyrocytes may drive anti-apoptotic pathways which would be expected to drive the autoimmune response towards GD. These two potential mechanisms are not mutually exclusive, as an inflamed thyrocyte may function as a more efficient facultative APC. Both the intrinsic and extrinsic mechanisms could be expected to be B-cell-assisted, as a B cell expressing more CD40, as in the context of the C Kozak allele, would be expected to have a lower threshold for activation and exhibit a greater propensity towards self-reactivity. It should be noted, however, that these two hypothetical mechanisms are purely speculative, at this stage, and await experimental validation.
In addition to MG, which is an antibody-mediated autoimmune disease, the CD40 Kozak SNP was tested for association with HT 17 and multiple sclerosis (MS), 61 which are considered T-cell-mediated autoimmune disease. The CD40 SNP was not found to be associated with HT 17 and MS. 61 Moreover, we found no linkage of the CD40 gene locus with HT.
11 Therefore, so far CD40 was found to be linked and associated only with GD. Interestingly, a systemic lupus erythematosus (SLE) locus was identified on chromosome 20q close to the CD40 gene. 62 Moreover, Gaffney et al. 62 found an association between a SNP (rs2064405) which is located 20 kb downstream from the CD40 (TNFRSF5) gene and SLE. Therefore, it would be very interesting to test the CD40 Kozak SNP for association with SLE.
One limitation of our study is the relatively small size of some of the subsets, making it difficult to detect modest associations to disease (ORs of o2.15 and 2.85, for MG and MG þ TPO/Tg Ab, respectively, Table 3 ). However, our P-values did not approach any significant level; hence, it would be unlikely that an association would emerge in an even larger data set size. Additionally, it cannot be precluded that a CD40 Kozak SNP analysis conducted on patients having both MG and GD concurrently could have yielded an association with the SNP. However, such a dual-disease phenotype study, as informative as it may be, would be difficult to carry out due to the extremely limited number of potential patients, as approximately only one among 6840 people have MG, 63 of whom only 10-15% can be expected to have some form of AITD. [64] [65] In summary, our data suggest that specific autoimmune disease genes exist, as CD40 seems to be specific for GD. Moreover, our results support the concept that a single autoimmune phenotype may have a number of different subsets, reflecting different relative contributions of a several susceptibility genes. In the case of GD, the CD40 Kozak SNP was associated with a disease phenotype characterized by persistent TPO/Tg Ab after therapy and restoration of euthyroidism. The significance of these disease subsets to design disease specific therapies remains to be determined. However, it is possible that the CD40 pathway could represent a new therapeutic target in GD.
Materials and methods

Patients and controls
The project was approved by the institutional review board (IRB).
GD patients. Two hundred and ten Caucasian GD patients were tested in our association studies. GD was diagnosed by (1) documented clinical and biochemical hyperthyroidism requiring treatment, (2) a diffuse goiter and (3) the presence of thyroid stimulating hormone (TSH) receptor antibodies and/or a diffusely increased 131 I uptake in the thyroid gland. TSH receptor antibodies were measured by the Kronus radioimmunoassay kit (Kronus, Boise, ID, USA). Of the GD patients, 126 had persistently elevated thyroid antibodies (TPO/Tg Abs) after treatment, 44 had no TPO/Tg Abs, and in 40 GD patients the TPO/Tg Ab status after therapy was unknown.
MG patients. Eighty-six MG patients were studied. MG was diagnosed by classical and clinical findings and the presence of AchR autoantibodies. Twenty-two of the MG patients (26%) had clinical thyroid autoimmunity and 46 MG patients (53%) were positive for TPO/Tg Abs.
TPO/Tg Ab-positive patients. Forty-eight healthy individuals, who were found to have positive TPO/Tg Abs (either TPO/Tg Abs), were also studied. Anti-thyroglobulin and anti-TPO antibodies were measured by specific radioimmunoassay kit (Kronus, Boise, ID, USA).
Controls. Two hundred and seventy-one healthy Caucasian volunteers served as controls in our association studies. All controls had no personal or family history of thyroid disease or other autoimmune disease, and no goiter on examination; they had normal thyroid functions and were negative for thyroid autoantibodies.
DNA preparation DNA was extracted from whole blood using the Puregene kit (Gentra Systems, Minneapolis, MN, USA).
Analysis of the CD40 Kozak SNP The CD40 Kozak SNP was analyzed by an automated fluorescent-based restriction fragment length polymorphism analysis as described previously. 12 Briefly, DNA was amplified using the following primer pairs: forward primer 5 0 -CCTCTTCCCCGAAGTCTTCC-3 0 ; reverse primer -5 0 -GAAACTCCTGCGCGGTGAAT-3 0 . The forward primer was fluorescently labeled. PCRs were performed in a 20 ml reaction mixture containing 50 ng genomic DNA, 5 pmol of each primer (one of which was fluorescence-labeled), PCR buffer containing 50 mmol/l KCl, 10 mmol/l Tris-HCl (pH 8.3), 1.5 mmol/l MgCl 2 , 200 mmol/l of each deoxy (d)-ATP, dGTP, dTTP and dCTP; and 1 U of AmpliTaq DNA polymerase (PE Applied Biosystems, Foster City, CA, USA). Reaction mixtures were heated to 941C for 7 min, and then cycled 30 times as follows: 30 s at 941C, 30 s at 551C and 30 s at 721C. Fluorescently labeled PCR products were incubated at 371C with the restriction enzyme Sty1 for 2 h. The digested PCR product was diluted 1:25 in ddH 2 O, denatured and separated on an ABI-310 genetic analyzer (PE Applied Biosystems). The two alleles were easily separated using the following method: the T allele, resulted in a digested PCR product with two fragments of 203 and 99 bp, but only the 203 bp fragment was visualized as it contained the fluorescence labeled forward primer; the C allele, resulted in a digested PCR product with three fragments of 129, 74 and 99 bp; as the 129-bp fragment contained the fluorescentlylabeled forward primer it was visualized on the ABI-310. Allele typing was performed using Genotyper 2.0 software. CD40, CD19, and CD20 mRNA expression in different tissues Quantitative RT-PCR analysis. Total mRNA was purified from thyroid and skeletal muscle tissue (obtained from NDRI, Philadelphia, PA, USA) and blood, using the PrepEase kit (USB, Cleveland, OH, USA). Additionally, total mRNA from various tissues (skeletal muscle, spleen, trachea, thymus, brain, ovary, thyroid and lymph node) was purchased from Stratagene (La Jolla, CA, USA). Two hundred nanograms of RNA were used to make cDNA, using the random primer method of the StrataScript First-Strand Synthesis System kit (catalog no. 200420; Stratagene). CD40 expression was assessed by quantitative RT-PCR, using forward primer 5 0 -GCATG CAGAGAAAAACAGTA-3 0 and reverse primer 5 0 -GATGG TGTCTGTTTCTGAGG-3 0 . Levels of CD40 mRNA were normalized against a b-actin control, which was determined using the following primer pairs: forward 5 0 -CATCAGCGAAGCAGAAGGC-3 0 and reverse 5 0 -GGCC AGCGTTTCTTGAGTCT-3 0 . Sequences for human CD19 primers were as follows: forward 5 0 -TCCACCTGGA GATCACTGCT-3 0 and reverse 5 0 -AAGGGAACACAGG CAGAAGA-3 0 . Sequences for CD20 primers were as follows: forward 5 0 -AACCAGCTAATCCCTCTGAGAA-3 0 and reverse 5 0 -GAAGGCAAAGATCAGCATCACT-3 0 . All quantitative RT-PCRs were run, using the Brilliant SYBR Green QPCR Master Mix kit (Stratagene), according to the manufacturer's protocol. Data were collected using the Smart Cycler from Cepheid (Sunnyvale, CA, USA) and analyzed by the Q-gene program. 66 Western blot analysis. Western blot analyses were used to compare CD40 expression levels on B cells, thyroid and skeletal muscles. Human peripheral B cells were isolated from volunteers, as described previously. 21 Human skeletal muscle was obtained from the National Disease Research Interchange (Philadelphia, PA, USA). Human thyroidal tissue was obtained from the healthy lobe of cancerous thyroids that were excised, during surgery (kindly provided by Dr Yuri Nikiforov, University of Cincinnati). Surface CD40 was dissociated from cell membranes, based on the methodology employed by Ferrari et al. 67 In brief, tissues or cells were thawed in 50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 0.5% Triton, 2 mM ethylenediaminetetraacetic acid, in the presence of a protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA, catalog no. 04 693 116 001). One tablet was added per 50 ml of buffer. Samples were incubated on ice, and after 15 min, were centrifuged at 16 000 g for 10 min. Supernatants were then collected and were measured for their protein content. Protein was quantified using the Bio-rad protein assay dye reagent (Bio-rad, Hercules, CA, USA, catalog no. 500-0006). A standard curve was constructed using bovine serum albumin (Bio-rad protein assay standard, catalog no. 500-0007). Before loading, samples were heated at 951C for 2-3 min, under reduced conditions.
Ten micrograms of sample protein was loaded per lane. Size standards consisted of pre-stained protein markers from New England Biolabs (Beverly, MA, USA, catalog no. P7708S). BJAB cell lysate was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA, catalog no. sc-2207). Samples were run on a 12% polyacrylamide gel, and after electrophoresis were transferred to a 0.45 mm nitrocellulose membrane (Bio-rad, catalog no. 162-0214). Subsequent to the transfer, the nitrocellulose membrane was incubated for 1 h in 10% dried milk/ phosphate-buffered saline (PBS). After washing with PBS, the membrane was incubated, for 1 h, with a rabbit anti-human CD40 antibody (Santa Cruz Biotechnology. Santa Cruz, CA, USA, catalog no. sc-975), diluted 1:1000, in 10% milk/PBS/0.1% Triton-X-100. After washing with PBS/0.1%Triton-X-100, a horseradish peroxidase (HRP)-conjugated goat-anti-rabbit IgG antibody (Pierce Biotechnology, Inc., Rockford, IL, USA, catalog no. 31462) was applied, for 1 h, at a 1:500 000 dilution, in 10% milk/ PBS/0.1% Triton-X-100. The blot was again washed with PBS/0.1% Triton-X-100, and after washing, it was developed using supersignal west femto maximum sensitivity substrate (Pierce Biotechnology Inc., Rockford, IL, USA, catalog no. 34095) and exposing to X-ray film.
For CD22 analyses, the blot previously probed for CD40 was stripped, Restore TM Western Blot Stripping Buffer (Pierce Biotechnology Inc., Rockford, IL, USA, catalog no. 21059). Blocking, washing, incubation times and developing were performed, as done for CD40. The primary antibody used was a mouse monoclonal antihuman CD22 (BD Transduction Laboratories, San Jose, CA, USA, catalog no. 612462), diluted 1:2000 in 10% milk/PBS/0.1% Triton-X-100. The secondary antibody used was an HRP-conjugated goat anti-mouse IgG antibody (Pierce Biotechnology, Inc., Rockford, IL, USA, catalog no. 31446), diluted 1:200 000 in 10% milk/PBS/ 0.1% Triton-X-100.
Three different CD40/CD22 gels were separately run and analyzed; they showed identical results.
Statistical analysis
All the marker genotyping data were exported to a database (Oracle), where they were integrated with existing phenotype information and prepared for association analyses. Case-control association analyses were performed using the w 2 and Fisher's exact tests with Yates correction. The OR was calculated by the method of Woolf. 68 Analysis of quantitative RT-PCR was performed using a non-paired two-tailed t-test. A P-value of o0.05 was considered significant.
Power calculations
We used the centers for disease control and prevention (CDC) simulation software (Epi Info, Version 6.03, CDC, Atlanta, GA, USA) to define the information limits of our experimental results. Our power calculations assumed 271 controls (the number of controls in our data set), and a varying number of patients depending on the subset studied as follows: n ¼ 210 for the GD group (the number of GD patient's genotypes); n ¼ 126 for the GD þ TPO/Tg Ab subset; n ¼ 81 for the MG (in 81 MG patients unequivocal genotyping was obtained); and n ¼ 42 for the MG þ TPO/Tg Ab subset. We assumed the population frequency of the susceptibility genotype (CC) to be 50% for the CD40 Kozak SNP based on our published data (12) . Our power calculations indicated that our data set of controls and different subsets of patients would give our study 80% power to detect a difference between the patients and the controls resulting in an OR of 41.7-2.8 (depending on the subset) with an a of 0.05 (Table 3) .
